基本信息
浏览量:176
职业迁徙
个人简介
My scientific training is in the field of molecular biology, molecular cytogenetics and cancer genomics. Prior to joining the Henry Ford Health System, I was working as an Associate Professor at the Michigan Center for Translational Pathology (MCTP), and a group leader in cancer biology at the Genome Institute of Singapore (GIS) where I established the molecular cytogenetics laboratory and conducted research on the identification and characterization of gene fusions in solid tumors, with particular emphasis on breast cancer and gastric cancer. Prior to joining GIS, I was the founding scientist and Director of Research and Development, in the Genomics Research division of Cancer Genetics, Inc. (CGIX). During my tenure there I introduced novel approaches in FISH probe development for the routine diagnosis of recurrent chromosome translocations in cancer at high specificity and sensitivity. Based on the new approaches obtained two US patents. I developed and commercialized about 40 FISH probes for the detection of non-random chromosome translocations and other recurrent chromosome abnormalities present in lymphomas and leukemias. My research work at CGI was supported by three consecutive Phase I and one Phase II SBIR grant applications (~$2 million) funded by NCI.
My current research interests are centered on the discovery and characterization of gene fusions in solid cancer and their role in carcinogenesis from a translational research perspective. I have been using genomic technologies such as aCGH, FISH, SKY, gene expression microarrays, and next-generation sequencing (NGS) to interrogate the transcriptional and genomic architecture of solid cancer genome. At the DNA level, in-depth analyses using high resolution technologies to study copy number changes, particularly genomic amplifications and deletions, have identified rare gene fusions formed at the boundaries of copy number changes. Successfully applied next generation sequencing technology for transcriptome sequencing and discovered new recurrent gene fusions in cancer. The primary goal of this approach is to identify novel gene fusions specific for each cancer type. The discovery of recurrent RAF gene fusions in non ETS prostate cancer and identification of cancer specific expression of pseudogenes was made possible by these novel computational approaches.
Emerging evidence show that cancer can be classified based on molecular aberrations rather than morphological and histological subtypes for each tissue type. ETS family genes are difficult to target with small molecule inhibitors due to the lack of enzymatic activity and requirement of interaction with proteins to attain specificity. While screening the ETS negative prostate cancers by transcriptome sequencing we discovered novel recurrent druggable RAF kinase pathway gene fusions. Extended analysis in other solid cancer revealed the RAF gene rearrangements in gastric cancer and melanoma. These RAF gene fusions are targetable with BRAF and MEK inhibitors. This finding is a significant advancement in the identification and treatment of subsets of patient population with RAF family gene rearrangement.
With the identification of new molecular markers in prostate cancer, currently our research work in focused on understanding tumor molecular heterogeneity in multifocal prostate cancer with the goal of understanding the impact of inter and intra tumor heterogeneity in tumor progression and response to treatment.
研究兴趣
论文共 332 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nallasivam Palanisamy, Wei Zhao,Pin Li,Shannon Carskadon,Sunita Ghosh,Craig Rogers,James Peabody, Dhananjay Chitale,Mani Menon, Sean Williamson,Nilesh Gupta
medrxiv(2024)
iScienceno. 3 (2024): 108794-108794
openalex(2023)
Nallasivam Palanisamy,Jun Yang,Peter D.A. Shepherd,Elsa M. Li-Ning-Tapia,Estefania Labanca,Ganiraju C. Manyam,Murali K. Ravoori,Vikas Kundra,John C. Araujo,Eleni Efstathiou,Louis L. Pisters,Xinhai Wan,Xuemei Wang,Elba S. Vazquez,Ana M. Aparicio,Shannon L. Carskadon,Scott A. Tomlins,Lakshmi P. Kunju,Arul M. Chinnaiyan,Bradley M. Broom,Christopher J. Logothetis,Patricia Troncoso,Nora M. Navone
crossref(2023)
Cancer Researchno. 7_Supplement (2023): 140-140
Vasudha Murlidhar,Rishindra M. Reddy,Shamileh Fouladdel,Lili Zhao,Martin K. Ishikawa, Svetlana Grabauskiene,Zhuo Zhang,Jules Lin,Andrew C. Chang, Philip Carrott, William R. Lynch,Mark B. Orringer,Chandan Kumar-Sinha,Nallasivam Palanisamy,David G. Beer,Max S. Wicha,Nithya Ramnath,Ebrahim Azizi,Sunitha Nagrath
crossref(2023)
crossref(2023)
Nallasivam Palanisamy,Jun Yang,Peter D.A. Shepherd,Elsa M. Li-Ning-Tapia,Estefania Labanca,Ganiraju C. Manyam,Murali K. Ravoori,Vikas Kundra,John C. Araujo, Eleni Efstathiou,Louis L. Pisters,Xinhai Wan,Xuemei Wang,Elba S. Vazquez,Ana M. Aparicio,Shannon L. Carskadon,Scott A. Tomlins,Lakshmi P. Kunju,Arul M. Chinnaiyan,Bradley M. Broom,Christopher J. Logothetis,Patricia Troncoso,Nora M. Navone
crossref(2023)
Nallasivam Palanisamy,Jun Yang,Peter D.A. Shepherd, Elsa M. Li-Ning-Tapia,Estefania Labanca,Ganiraju C. Manyam,Murali K. Ravoori,Vikas Kundra,John C. Araujo,Eleni Efstathiou,Louis L. Pisters,Xinhai Wan,Xuemei Wang,Elba S. Vazquez,Ana M. Aparicio,Shannon L. Carskadon,Scott A. Tomlins,Lakshmi P. Kunju,Arul M. Chinnaiyan,Bradley M. Broom,Christopher J. Logothetis,Patricia Troncoso,Nora M. Navone
crossref(2023)
Kathleen C. Day,Guadalupe Lorenzatti Hiles,Molly Kozminsky,Scott J. Dawsey,Alyssa Paul,Luke J. Broses,Rajal B. Shah, Lakshmi P. Kunja,Christopher Hall,Nallasivam Palanisamy,Stephanie Daignault−Newton,Layla El-Sawy, SJ Wilson,Andrew Chou,Kathleen M. Woods Ignatoski,Evan T. Keller,Dafydd G. Thomas,Sunitha Nagrath, Todd M. Morgan,Mark L. Day
openalex(2023)
加载更多
作者统计
#Papers: 335
#Citation: 19829
H-Index: 65
G-Index: 140
Sociability: 7
Diversity: 0
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn